Reported Sunday, Xenon Presents Phase 3 X-TOLE2 Data Showing Azetukalner Delivers 53.2% Reduction In Monthly Seizure Frequency Versus 10.4% For Placebo In Focal Onset Seizures At AAN 2026
Benzinga Newsdesk 6 months ago
News
Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time pointsX-TOLE2 data featured in the Late-breaking Science session show 53.2% reduction in monthly seizure
- Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time points
- X-TOLE2 data featured in the Late-breaking Science session show 53.2% reduction in monthly seizure frequency in 25 mg group vs. 10.4% for placebo and increasing rates of 100% seizure reduction over time during 12-week double-blind period
- Long-term data from the ongoing X-TOLE OLE study at 48 months show nearly 40% of participants achieving at least 12 months of seizure freedom and one in four participants achieving at least 24 months of seizure freedom
- Real-world data reinforce the value of anti-seizure medications that do not require titration to reduce stress and simplify focal seizure management for both patients and physicians